Focal or subtotal therapy for early stage prostate cancer.
Focal treatment for prostate cancer is highly intriguing, but poorly supported by the published literature. Further studies, preferably randomized controlled trials, are needed before this can be considered standard therapy. Focal treatment should be reserved for patients with focal disease. Even "clinically insignificant" synchronous tumors are malignant, and carry risk of progression if not treated with the index lesion. Whether these are likely to progress in this setting compared to those managed with active surveillance is unknown. The limited data regarding subtotal or focal cryotherapy suggest that patients properly evaluated for presence of satellite tumors have a low risk of having large unknown satellite tumors. The author requires office-based saturation biopsy prior to considering focal cryotherapy. Observation of prostatic intraepithelial neoplasia (PIN), atypical findings (ASAP), or cancer on the contralateral biopsy cores excludes the patient from consideration of subtotal therapy. MRI offers a potential additional ability to detect occult contralateral tumors. Younger men paradoxically seem to have greater interest in focal therapy while having a higher risk of future malignancy in the untreated areas based on the years of potential risk. However, no age cutoff is established. Without published data to support its use, lumpectomy or freezing only the focus where cancer is believed to exist, will remain limited. Hemispheric or subtotal treatment decreases the amount of untreated tissue. As a result, the local failure rate would be predicted to be lower but is unknown. When performing subtotal treatment, the author freezes almost the entire gland, sparing only the aspect adjacent to the contralateral neurovascular bundle, and has found this practice to be of highly limited utility based on the issues described. Biopsy should be performed following any treatment that fails to target the entire gland. A positive biopsy should be dealt with based on clinical factors as if the patient had not been treated, and a positive biopsy should not preclude active surveillance if deemed appropriate.
Jones
J Stephen
JS
Urological Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave St. A100, Cleveland, OH 44195, USA. jonesS7@ccf.org
D001918:Brachytherapy / Q000379:methods; D017679:Cryotherapy / Q000379:methods; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D014463:Ultrasonography
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):429-38
11872289
Semin Nucl Med. 2007 Jan;37(1):17-28
17161036
Brachytherapy. 2007 Jan-Mar;6(1):16-25
17284381
Cancer. 1972 Jul;30(1):5-13
5064808
J Urol. 2004 Apr;171(4):1520-4
15017211
Urology. 2002 Jul;60(1):109-14
12100934
Technol Cancer Res Treat. 2004 Aug;3(4):365-70
15270587
J Urol. 2002 Aug;168(2):500-3
12131297
Technol Cancer Res Treat. 2007 Apr;6(2):91-5
17375971
Urology. 2005 Jul;66(1):114-8
15992910
Urology. 2002 Aug;60(2 Suppl 1):3-11
12206842
Urology. 2001 Jun;57(6):1112-6
11377320
Urology. 2002 Oct;60(4):645-9
12385926
J Urol. 1998 Mar;159(3):915-9
9474182
Urology. 2007 Feb;69(2):306-10
17320669
Eur Urol. 2007 Feb;51(2):381-7
16857310
J Urol. 1994 Jun;151(6):1571-4
7514690
Urology. 2006 Nov;68(5):1037-41
17095067
Cancer. 1992 Nov 1;70(9):2313-8
1382830
J Urol. 1999 Nov;162(5):1649-52
10524890
Urology. 1999 Nov;54(5):846-52
10565745
Eur Radiol. 2004 Feb;14(2):309-17
14531000
J Urol. 2006 Oct;176(4 Pt 1):1376-81; discussion 1381
16952636
Int J Impot Res. 1996 Jun;8(2):91-4
8858398
Eur Urol. 2006 Dec;50(6):1163-74; discussion 1175
16842903
World J Urol. 2006 Nov;24(5):585-90
16850340
Urology. 2002 Aug;60(2 Suppl 1):34-9
12206846
Urology. 2002 Aug;60(2 Suppl 1):19-25
12206844
Med Dosim. 2007 Summer;32(2):71-9
17472885
Am J Surg Pathol. 1992 Apr;16(4):315-24
1373577
Radiology. 1997 Jun;203(3):645-52
9169683
J Urol. 1999 Aug;162(2):433-8
10411052
J Endourol. 2006 Sep;20(9):688-92
16999628
Cancer Res. 1995 Aug 1;55(15):3346-51
7542168
Eur Urol. 2006 Sep;50(3):498-505
16631303